" class="no-js "lang="en-US"> ILC Therapeutics - Medtech Alert
Wednesday, July 30, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
ILC Therapeutics | Pharmtech Focus

ILC Therapeutics

About ILC Therapeutics

ILC Therapeutics

ILC Therapeutics™ Ltd is an early stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics. We have several patents in this area and our two lead compounds: ILCT 1001 and ILCT 1002 have been shown in numerous ways to affect the key cells involved in cancer, atopic dermatitis, and psoriasis.

Related Story

Fundraising

 ILC Therapeutics Announces Successful Completion of £3.5m Funding Round | Pharmtech Focus

ILC Therapeutics Announces Successful Completion of £3.5m Funding Round

September 7 2021

ILC Therapeutics, a UK-based biotechnology company and pioneer in the discovery and development of a […]